This product is a sulfonylurea antidiabetic drug, which is effective for most patients with type 2 diabetes. It can reduce fasting and postprandial blood sugar and reduce glycosylated hemoglobin (HbA1c) by 1%-2%. The main function of this type of drug is to stimulate the pancreatic beta cells to secrete insulin, but the prerequisite is that the pancreatic beta cells still have a certain function of synthesizing and secreting insulin. Its mechanism is to specifically bind to the sulfonylurea receptors on the beta cell membrane, thereby closing the K channel, causing changes in membrane potential, opening the Ca2 channel, and increasing the intracellular Ca2, which promotes insulin secretion. In addition, there are extra-pancreatic effects, including improving the insulin resistance of peripheral tissues (such as liver, muscle, and fat).

This product is a sulfonylurea antidiabetic drug, which is effective for most patients with type 2 diabetes. It can reduce fasting and postprandial blood sugar and reduce glycosylated hemoglobin (HbA1c) by 1%-2%. The main function of this type of drug is to stimulate the pancreatic beta cells to secrete insulin, but the prerequisite is that the pancreatic beta cells still have a certain function of synthesizing and secreting insulin. Its mechanism is to specifically bind to the sulfonylurea receptors on the beta cell membrane, thereby closing the K channel, causing changes in membrane potential, opening the Ca2 channel, and increasing the intracellular Ca2, which promotes insulin secretion. In addition, there are extra-pancreatic effects, including improving the insulin resistance of peripheral tissues (such as liver, muscle, and fat).

This product is a non-steroidal anti-inflammatory analgesic that can inhibit the synthesis of prostaglandins and exert anti-inflammatory and analgesic effects

This product is a non-steroidal anti-inflammatory analgesic that can inhibit the synthesis of prostaglandins and exert anti-inflammatory and analgesic effects.

This product is a non-steroidal anti-inflammatory analgesic that can inhibit the synthesis of prostaglandins and exert anti-inflammatory and analgesic effects.

This product is a non-steroidal anti-inflammatory analgesic that can inhibit the synthesis of prostaglandins and exert anti-inflammatory and analgesic effects.

This product is a non-steroidal anti-inflammatory analgesic that can inhibit the synthesis of prostaglandins and exert anti-inflammatory and analgesic effects.

This product is a non-steroidal anti-inflammatory analgesic that can inhibit the synthesis of prostaglandins and exert anti-inflammatory and analgesic effects.

Fluconazole is a triazole broad-spectrum antifungal drug that inhibits the reproduction and growth of fungi by highly selectively inhibiting the C-14-α-demethylation of fungal cytochrome P-450 sterols, causing the accumulation of 14-α-methyl sterols in fungi. In vitro tests have shown that this product has antibacterial activity against Cryptococcus neoformans and Candida species. Oral and intravenous injection of fluconazole in animals is effective in the following animal fungal infection models: Candida species infection (including systemic candida disease in immunodeficient animals); Cryptococcus neoformans infection (including intracranial infection); Microsporum and Trichophyton infections, etc. Fluconazole is also effective against Blastomyces dermatitidis infection and Coccidioides immitis infection (including intracranial infection); and is also effective against infections caused by Histoplasma capsulatum in normal animals and immunosuppressed animals.

This drug belongs to the 4-nitrogen steroid hormone compound and is a specific type II 5alpha;-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone, reduces the level of dihydrotestosterone in the blood and tissues such as the prostate and skin, and inhibits prostate hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissues, thereby improving the related clinical symptoms of benign prostatic hyperplasia.